MDS 2023 | What can artificial intelligence bring to the diagnosis and management of MDS?

So, we know that artificial intelligence is a new technology that is associated with a sort of revolution in different human domains, including medicine. With respect to the application of this new technology to the specific use case of myelodysplastic syndromes, we have to distinguish about two different types of and definition of artificial intelligence. The more traditional definition, that is artificial intelligence defined as machine learning, that is some methods that are aimed to create more efficient systems, processes, and data analysis by reducing the cost and the human effort. So, by using this traditional artificial intelligence, we can expect to improve the capability, for instance, for myelodysplastic patients to provide a more accurate diagnosis for each single individual and to provide a more robust prediction of the clinical outcome, including the probability of survival and leukemic evolution. But we have another type of artificial intelligence that is even more innovative, that is called generative artificial intelligence. The most famous type of this application is ChatGPT but we know that this technology can also be extremely useful for clinical medicine and in particular, this new type of artificial intelligence is able to generate new evidence from already available data. So that means to create it, not previously existing value. So in this point, in this specific situation, we can try to experience even a more helper and a more efficient application of this technology for improving the management and the clinical care of patients with milder dysplastic syndromes.